Mironid


Mironid logo

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Contact Mironid via their website


News archive

11/05/2017   Mironid CSO published in Journal of Clinical Investigation (JCI)...more
07/03/2017   Mironid will be attending Bio Europe Spring in Barcelona...more
06/02/2017   Mironid co-founders publish in The Biochemical Journal...more
01/02/2017   Sygnature Discovery, Mironid, and Peak Proteins to collaborate...more
30/01/2017   Mironid announces Early Stage Award from Innovate UK’s Biomedical Catalyst...more
05/01/2017   Mironid COO, Neil Wilkie, is attending JPM and Biotech Showcase conferences...more
05/01/2017   Dr George Muller joins Mironid's Scientific Advisory Board...more

12/12/2016   Mironid and University of Sheffield Announce Collaboration on ADPKD Drug Discovery...more
08/12/2016   Prof Albert Ong has joined Mironid's Scientific Advisory Board...more
07/12/2016   Mironid has appointed Dr Peter Webborn as DMPK consultant...more
24/11/2016   Read Mironid's Blog Post for Global Entrepreneurship Week - Scotland...more
17/11/2016   Mironid joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code